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trans-SNARE complex assembly and yeast vacuole
membrane fusion
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Contributed by William T. Wickner, March 28, 2007 (sent for review January 26, 2007)
cis-SNARE complexes (anchored in one membrane) are disassem-
bled by Sec17p (-SNAP) and Sec18p (NSF), permitting the unpaired
SNAREs to assemble in trans. We now report a direct assay of
trans-SNARE complex formation during yeast vacuole docking.
SNARE complex assembly and fusion is promoted by high concen-
trations of the SNARE Vam7p or Nyv1p or by addition of HOPS
(homotypic fusion and vacuole protein sorting), a Ypt7p (Rab)-
effector complex with a Sec1/Munc18-family subunit. Inhibitors
that target Ypt7p, HOPS, or key regulatory lipids prevent trans-
SNARE complex assembly and ensuing fusion. Strikingly, the lipid
ligand MED (myristoylated alanine-rich C kinase substrate effector
domain) or elevated concentrations of Sec17p, which can displace
HOPS from SNARE complexes, permit full trans-SNARE pairing but
block fusion. These findings suggest that efficient fusion requires
trans-SNARE complex associations with factors such as HOPS and
subsequent regulated lipid rearrangements.
homotypic fusion and vacuole protein sorting  Rab/Ypt
Regulated membrane fusion is essential for cell compartmen-tation. Intracellular fusion requires Rab-family GTPases,
Rab-effector complexes, Sec1/Munc18 proteins, key regulatory
lipids, and SNARE proteins (1). Most SNARE proteins are
membrane-bound by a C-terminal apolar region or by a prenyl
tail. SNARE proteins have membrane-proximal heptad repeat
sequences, termed the SNARE motif. These proteins associate
in alpha-helical, coiled-coil bundles as heteromeric SNARE
complexes (2). Three glutamine residues and one arginine
residue at the center of the four associated SNARE motifs,
termed the zero layer, have a conserved role in SNARE function
and categorize each SNARE as either Q- or R-SNARE (3).
SNARE complexes are in cis when their apolar anchors are all
in the same membrane bilayer or in trans when these anchors are
in closely apposed membranes, poised for fusion (4). SNAREs
and SNARE complexes associate with other factors, including
Sec1/Munc18 proteins (5, 6), Ca2-sensors such as synaptotag-
min (7–9), and others (10–12), for fusion. trans-SNARE pairs
may promote membrane fusion by inducing local physical stress
on the bilayer (13), destabilizing bilayer structure through their
slanted transmembrane domains (14), or enriching membrane
destabilizing lipids such as diacylglycerol at the fusion site (15).
Despite their importance, there have been few reports of direct
physical assay of trans-SNARE pairs (4, 16, 17).
We study membrane fusion with vacuoles from Saccharomyces
cerevisiae. Vacuole fusion requires the Rab GTPase Ypt7p, its
hexameric effector HOPS (homotypic fusion and vacuole pro-
tein sorting) complex, three Q-SNAREs (Vam3p, Vti1p, and
Vam7p), one R-SNARE (Nyv1p), and key ‘‘regulatory’’ lipids
(ergosterol, diacylglycerol, and phosphoinositides). At the start
of in vitro vacuole fusion reactions, the chaperones Sec18p (yeast
NSF) and Sec17p (-SNAP) disassemble cis-SNARE com-
plexes, freeing the SNAREs for association in trans. Vacuoles
tether, supported by Ypt7p (18) and HOPS (19), and are drawn
together until each pair of tethered vacuoles has disk-like regions
of ‘‘boundary’’ membrane that are tightly apposed (20). Each of
the key fusion factors (Ypt7p, HOPS, the SNAREs, and the
regulatory lipids) become enriched at a ring-shaped microdo-
main surrounding the boundary membrane, termed the vertex
ring (15, 20). SNARE pairing follows some time later and leads
to complete fusion.
Yeast vacuoles isolated from vam3 or nyv1 strains cannot
undergo homotypic fusion (21). However, vacuoles from vam3
strains fuse slowly with vacuoles from nyv1 strains, suggesting
that these SNAREs pair in trans (21). Assays of the physical
association of Vam3p and Nyv1p from vacuoles from nyv1 and
vam3 strains, respectively, offered a direct assay of trans-
SNARE pairing (4). However, these studies did not adequately
distinguish SNARE pairs that were truly in trans from those that
may have been trans but had been rendered cis by fusion, or from
those that were formed de novo in cis after fusion. Engineering
epitope tags on different SNAREs may permit the distinction
between cis and trans complexes with vacuoles that are otherwise
wild type in their fusion activity (17). We now report an assay of
trans-SNARE complex formation with vacuoles that undergo
normal rates and extents of fusion. Each vacuolar constituent
that is needed for vertex ring enrichment is needed for trans-
SNARE pairing, but either the phosphoinositide ligand myris-
toylated alanine-rich C kinase substrate effector domain (MED)
or an excess of the SNARE chaperone Sec17p permit trans-
SNARE complex formation while blocking the progression to
fusion.
Results
We now combine an assay of trans-SNARE pairing with our
standard fusion assay (22), in which proteases in vacuoles
prepared from a pho8 strain gain access to the proPho8p in
vacuoles from a pep4 strain and convert it to active Pho8p
phosphatase. For epitope-tagged SNAREs to be useful in trans-
SNARE pairing assays, the tag must be stable, in vivo and during
vacuole isolation and incubation. Fusion must proceed at normal
rates when the tagged SNAREs are the only forms of those
SNAREs in a fusion reaction; otherwise, the fusion of vacuoles
from X-vam3, NYV1 with vacuoles from VAM3, Y-nyv1, where
X and Y are fused epitopes, might be mediated by the wild-type
Vam3p and Nyv1p. It is therefore necessary to assay the fusion
of X-vam3, Y-nyv1, pep4 and X-vam3, Y-nyv1, pho8 vacuoles
to ensure that the fusion functions of the tagged SNAREs are
intact. Finally, to assay SNARE physical associations, a tag
should allow for the specific isolation or detection of the tagged
SNARE. We surveyed many fusions to the N or C terminus of
Vam3p and Nyv1p and found that none fulfilled all of these
criteria. We therefore surveyed sites of insertion of a short
(25-residue) calmodulin-binding peptide (CBP) sequence (23),
and found that its insertion into the coding sequence of Vam3p
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(Fig. 1A) did not disturb vacuole morphology, either in an
otherwise wild-type strain (Fig. 1 B vs. C) or in the nyv1
background (Fig. 1 D vs. E). Nyv1p is the major R-SNARE that
mediates vacuole fusion, but the ability of other R-SNAREs to
substitute for its function (24) allows nyv1 strains to have
normal vacuole morphology (Fig. 1D) as previously reported
(21). Vacuoles from pep4 or pho8 strains expressing wild-type
Vam3p or CBP-Vam3p shows normal levels of other SNAREs,
HOPS subunits, or the Rab Ypt7p (Fig. 1G). Although we do see
a synthetic defect in Vam7p localization to the vacuole when the
CBP-Vam3p is paired with nyv1 (Fig. 1G, compare lanes 2 and
3), we can add recombinant Vam7p to fusion assays.
trans-SNARE pairing can be assayed with a mixture of
vacuoles bearing CBP-Vam3p, nyv1, and vacuoles with wild-
type SNAREs, where the CBP-Vam3p from one fusion partner
associates with Nyv1p from the other, whereas the wild-type
Vam3p faces no Nyv1p at all on its fusion partner. We therefore
systematically tested the functionality of the CBP-Vam3p in the
presence or absence of Nyv1p on vacuoles from our pep4 and
pho8 tester strains (Fig. 2A). Fusion required physiological
temperature, was blocked by Gdi1p (which extracts Ypt7p), and
required Nyv1p in at least one fusion partner, as previously
reported (21). The presence of CBP-Vam3p on either or both
fusion partners had a modest effect on fusion, reducing fusion to
50% (Fig. 2 A). In the absence of Nyv1p on one fusion partner,
further reduction of fusion was seen. However, fusion activity is
restored in all cases by the addition of the Vam7p SNARE to the
assays (Fig. 2 A, open bars). Thus, CBP-Vam3p can mediate
fusion when it provides the only source of Vam3p.
To determine whether CBP-Vam3p could directly interact
with Nyv1p from acceptor membranes, vacuoles bearing CBP-
Vam3p and deleted for Nyv1p were incubated with vacuoles with
wild-type Vam3p and Nyv1p. Vacuole membranes were sedi-
mented, solubilized in detergent, and the CBP-Vam3p was
recovered with immobilized Ca2/calmodulin. CBP-Vam3p
bound 1% of the Nyv1p from the acceptor vacuoles and
reached a steady-state level of associations by 30 min (Fig. 2B,
lanes 5–6) while fusion continued beyond this time. The other
vacuolar SNAREs, Vam7p and Vti1p, showed coincident in-
crease in CBP-Vam3p associations. Because these CBP-Vam3p
vacuoles lack cis-SNARE complexes with Nyv1p, our findings
suggest that association with Nyv1p in trans may stabilize Vti1p
and Vam7p interactions with CBP-Vam3p. When detergent
extracts from reactions containing only a single vacuole type
were mixed, CBP-Vam3p showed little association with other
SNAREs (Fig. 2B, lane 10). Thus Nyv1p is required for stable
SNARE complex assembly, but it remained unclear whether
these SNARE associations occur before fusion, form merely as
a consequence of fusion, or some combination of the two.
We therefore tested various vacuole fusion inhibitors on the
assembly of SNARE complex between Nyv1p and CBP-Vam3p.
Vacuole fusion occurs in four functionally distinct stages: prim-
ing, tethering, docking, and fusion. Initially, vacuoles have
unpaired Nyv1p, Vam3p, and Vti1p, bound by their C-terminal
apolar anchor domains; however, the Vam7p SNARE, which has
no apolar domain, is not stably bound to the vacuole without
association with other SNAREs (6, 24). Priming is only needed
to release free Vam7p for trans-SNARE complex assembly, as
the addition of recombinant Vam7p allows fusion when priming
is blocked (24). Although antibodies to Sec17p or to Sec18p
prevent Nyv1p association with CBP-Vam3p and fusion (Fig. 3A,
lanes 5 and 6), even low levels of added Vam7p stimulate fusion
(lane 8 vs. 4) and relieve the ability of priming inhibitors to block
fusion and Nyv1p associations with CBP-Vam3p (lanes 9 and
10). Elevated concentrations of Sec17p can block SNARE
complex assembly (Fig. 3A, lane 7), but even in the presence of
recombinant Vam7p, added Sec17p blocks fusion while permit-
ting Nyv1p associations with CBP-Vam3p (lane 11). Thus nor-
mal cis-SNARE complex disassembly is required for subsequent
SNARE complex assembly, and Nyv1p can enter a prefusion
trans-SNARE complex with CBP-Vam3p.
Tethering, which requires Ypt7p and HOPS, is needed for
SNARE pairing (Fig. 3B). The extraction of Ypt7p by added
Gdi1p (Fig. 3B, lane 6), the premature activation of its GTPase
activity by recombinant Gyp1–46p (lane 7), their combined
actions (lane 8), or the addition of an antibody to Ypt7p (lane
9) prevents SNARE complex assembly and vacuole fusion.
Antibody inhibition of both fusion and SNARE pairing is
relieved by preincubating the antibody with its cognate peptide
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KVHA HCHB
Fig. 1. Vam3p bearing an internal epitope tag is functional in vivo. (A)
Vam3p domain structure. A CBP was inserted between the helices ABC N-
terminal domain and the SNARE domain. The CBP was inserted N-terminal to
the dileucine sorting motif. (B–F) Vacuole morphology in yeast cells expressing
wild-type Vam3p or CBP-Vam3p. Overnight cultures of BJ3505 yeast cells and
derivatives were stained in YPD with FM 4-64 (5 M). Cells were concentrated
by centrifugation, applied to glass slides, and overlaid with a coverslip. Mi-
crographs of stained vacuoles were acquired as described (6). (G) Protein
composition of isolated yeast vacuoles. Vacuoles from the indicated strains
were heated in sample buffer. Proteins were separated by SDS/PAGE (5 g per
lane), transferred to nitrocellulose, and incubated with the indicated anti-
bodies. Because vacuoles prepared from DKY6281 have active proteases, some
protein degradation (e.g., Snc1/2p and Vps41p) occurred during isolation.
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tethering (19), and antibody to its Vps33p subunit blocks
SNARE pairing and fusion (Fig. 3B, lane 11). These results
confirm that GTP-bound Ypt7p and its effector HOPS have
functions before SNARE complex assembly.
Key regulatory lipids (ergosterol, diacylglycerol, and 3- and
4-phosphatidylinositides) are required for normal enrichment of
fusion components at the vertex ring (15, 25). HOPS binds to
phosphoinositides directly and through interaction with the PI
(3)P-binding PX domain of Vam7p (19). We explored whether
these lipids play a role during trans-SNARE complex assembly.
MTM-1, a PI (3)P-specific phosphatase, SigD, a PI(4,5)P2-
specific PI (5)P phosphatase, FAPP PH domain, a ligand of PI
(4)P, and ENTH domain, a ligand of PI(4,5)P2, all inhibit
trans-SNARE pairing (Fig. 4). We have previously reported that
the MED polypeptide, which interacts with PI(4,5)P2 and
PI(3,4)P2 (26), will prevent fusion but allow added Vam7p to
bind to vacuoles in association with the other SNAREs and
HOPS (6). We now find that this association includes trans-
SNARE complex formation, as fusion is effectively blocked (Fig.
4, lane 5). MED inhibition of fusion can be reversed by added
PI(4,5)P2 (27), which suggests that MED is not irreversibly
perturbing the vacuole membrane. Because we find that several
inhibitors that affect PI(4,5)P2 or its precursors also block
trans-SNARE complex assembly and fusion while MED only
prevents fusion, MED inhibition of vacuole fusion may reflect
other interactions in addition to PI(4,5)P2.
The levels of vacuolar trans-SNARE complex might be limited
by the stoichiometry or availability of one of its constituents,
such as one of the four SNAREs or perhaps HOPS, which
associates with SNARE complexes that assemble late in the
fusion reaction (6). As a result, trans-SNARE complex may be
kinetically favored by elevated concentrations of HOPS or any
of the SNAREs. We find that elevated concentrations of Vam7p
promote SNARE complex formation and fusion (Fig. 5A).
Added HOPS further stimulates trans-SNARE complex assem-
bly and fusion; this stimulation was not inhibited by MED and
thus occurs before fusion (Fig. 5A, lanes 7 and 8) while incuba-
tion with GDI and Gyp1–46p prevented this assembly (data not
shown). Furthermore, although Nyv1p is present on vacuoles in
stoichiometric excess over Vam3p (20), elevation of its level
through genetic overexpression on the acceptor vacuole mem-
branes (27) also enhanced trans-SNARE pairing and fusion (Fig.
5B, lanes 3 and 9; Y. Jun and W.T.W., unpublished data). This
ability of enhanced levels of Vam7p, Nyv1p, or HOPS to increase
the levels of prefusion trans-SNARE complex suggests that
the assembly rate is proportional to their steady-state levels,
rather than assembly being limited by the stoichiometry of one
constituent.
Discussion
Although trans-SNARE complexes are crucial intermediates in
fusion, their direct assay has been elusive and is often not
distinguished from the more abundant cis-SNARE complexes.
We now show that trans-SNARE assembly is sensitive to inhib-
itors of tethering, is promoted by elevated SNARE and Rab
effector concentrations, and occurs before aqueous compart-
ment mixing. Either elevated concentrations of Sec17p, a co-
using immobilized calmodulin on agarose beads (see Materials and Methods).
Two detergent extracts were also prepared from reactions containing a single
vacuole type, a CBP-Vam3p nyv1 vacuole reaction, or a DKY6281 vacuole
reaction. These two extracts were mixed and the CBP-Vam3p interactions with
Nyv1p that occur in solution were examined (lane 10). The experiment shown
was performed in duplicate and is representative of three independent trials.
Bars indicate the average fusion and Nyv1p associations as determined by
densitometry of the duplicates, and error bars represent the range of values
between them.
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Fig. 2. CBP-Vam3p promotes vacuole fusion and SNARE complex assembly in
vitro. (A) CBP-Vam3p, as the sole source of Vam3p, can mediate vacuole fusion.
Vacuoles were isolated from the indicated strains (pep4 is BJ3505 and pho8
is DKY6281) expressing the indicated SNAREs and assayed under standard
fusion conditions. Reactions were incubated at 27°C (or held on ice) for 90 min.
Where indicated, GDI (1 M), Sec18p (1.5 nM), or Vam7p (40 nM) were added
from the start. Bars represent the average fusion activity of two independent
experiments in which reactions bearing wild-type Vam3p and no fusion
activator or inhibitor (middle gray bar) was set to 100%. Error bars indicate the
range of the values in the two experiments. The asterisk highlights that
combination of yeast vacuoles used for subsequent trans-SNARE interactions
in this study. (B) Assay of SNARE complex assembly between CBP-Vam3p and
Nyv1p. Vacuoles bearing CBP-Vam3p and deleted for Nyv1p were mixed with
vacuoles from DKY6281. Reactions were incubated at 27°C for the indicated
times after which vacuole fusion (black bars) and the associations of CBP-
Vam3p with Nyv1p from the acceptor vacuoles (gray bars) and other SNAREs
was measured by affinity purification from detergent extracts








chaperone of cis-SNARE complex disassembly, or the lipid
ligand MED will allow trans-SNARE complex assembly while
preventing fusion.
Sec17p and MED may act through a shared inhibition of
HOPS–SNARE interactions. Without added Vam7p, Sec17p
prevents the vertex accumulation of HOPS and SNAREs (20,
25), physically disrupts HOPS–SNARE interactions (6), and
prevents trans-SNARE complex assembly (Fig. 3). Added
Vam7p bypasses the requirement for Sec17/18p function to
liberate Vam7p for trans-SNARE complex assembly (24). In the
presence of added Vam7p, elevated concentrations of Sec17p
permit trans-SNARE complex formation while preventing fu-
sion. Sec17p may block fusion through direct interactions with
the trans-SNARE complex. Recent studies of the binding of
Sec1/Munc18 proteins, complexin, and synaptotagmin to the
synaptic SNARE complex suggest intriguing parallels to our
results. Sec1/Munc18 proteins bind to SNARE complexes (28,
29). Complexin interacts with and stabilizes synaptic SNARE
complexes next to the membrane proximal region (10). Synap-
totagmin, when bound to Ca2, can displace complexin to
facilitate the transition from hemifusion to fusion (9, 30, 31).
Like complexin, Sec17p/SNAP binds to the SNARE complex
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Fig. 3. Control of trans-SNARE complex assembly. (A) Testing cis-SNARE
disassembly inhibitors and their bypass by Vam7p. Fusion reactions containing
trans-SNARE tester vacuoles were incubated with buffer alone (lanes 4 and 8),
antibodies to Sec17p (lanes 5 and 9) or Sec18p (lanes 6 and 10), or excess Sec17p
(750 nM; lanes 7 and 11). Vam7p was then added where indicated (lanes 8–11).
Reactions were incubated (27°C, 45 min) and fusion (black bars) and CBP-
Vam3p associations with Nyv1p (gray bars) and other SNAREs were assayed.
Data are representative of three independent experiments. Bars represent the
average fusion and Nyv1p associations found in three (without Vam7p) or four
experiments (with Vam7p). Error bars indicate the standard deviation of the
values obtained. (B) Role of Ypt7p and HOPS. Fusion reactions with 40 nM
Vam7p were incubated with buffer alone (lanes 4 and 5), GDI (lane 6),
Gyp1-46p (lane 7), GDI and Gyp1-46p (lane 8), antibodies to Ypt7p (lane 9),
antibodies to Ypt7p premixed with cognate peptide (lane 10), or antibodies to
Vps33p (lane 11). Reactions were incubated (27°C, 60 min), and fusion (Top)
and CBP-Vam3p association with other SNAREs assayed. Fusion values are the
average of three independent experiments and error bars represent the




















































































Fig. 4. Regulatory lipid requirements during trans-SNARE complex assem-
bly. Fusion reactions were incubated with Vam7p with no added inhibitors
(lane 1) or with the indicated inhibitors (lanes 2–6). After incubation (45 min,
27°C), reactions were placed on ice and fusion (black bars) and CBP-Vam3p
associations with Nyv1p (gray bars) and other SNAREs were assayed. Data are
representative of four experiments whose results were averaged; error bars
represent the standard deviation of the values obtained after densitometric
analysis of Nyv1p associations.
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HOPS has direct affinity for phosphoinositides and ligands to
phosphoinositides cause HOPS release from vacuoles (19).
Because HOPS promotes trans-SNARE complex assembly, we
suggest that HOPS binding to the SNARE complex is required
for HOPS and/or SNARE localization to the vertex for fusion,
consistent with a role for SNAREs in HOPS and lipid localiza-
tion (15, 25). Because Sec17p can block fusion after trans-
SNARE assembly, HOPS may stabilize the forward pathway and
directly occlude Sec17/18p-mediated trans-SNARE complex
disassembly. Just as synaptotagmin displaces complexin during a
late step of membrane fusion, Sec17p alone or in combination
with Sec18p may similarly be able to associate with the prefusion
trans-SNARE complex (4).
trans-SNARE pairing is undoubtedly required for fusion, but
it may not be rate limiting. Elevated concentrations of HOPS or
the SNAREs Vam7p or Nyv1p stimulate trans-SNARE assem-
bly to a greater extent than they promote fusion (Figs. 3 and 5).
Tethered vacuoles that are deprived of Vam7p undergo SNARE
pairing within minutes of its addition, yet complete fusion, as
assayed by aqueous compartment mixing, occurs much more
slowly (27). Lipid bilayer rearrangements are thought to be the
terminal events of fusion; our finding that MED blocks fusion
after trans-SNARE pairing is in accord with this idea. MED may
generally inhibit vacuolar lipid rearrangements or may interfere
with essential interactions of SNAREs with lipids (32). There are
conserved, basic residues in SNARE proteins between the
SNARE motif and the transmembrane domain (33). MED is a
basic polypeptide and may interfere with SNARE binding to
lipids during the transition from a proposed hemifusion inter-
mediate to aqueous compartment mixing. trans-SNARE pairs
may contribute to fusion through the enrichment of other fusion
factors (15, 20, 25), by aligning microdomains of the membrane
that are poised for fusion and by exerting physical stress on the
bilayer (13). There is no quantitative data as to the relative
importance of each of these to fusion. In each regard, it is of
fundamental importance to be able to directly measure trans-
SNARE assembly and fusion in an assay system with normal
rates of fusion.
Materials and Methods
Yeast Strains. The S. cerevisiae strains for the vacuole fusion assay
include BJ3505 [MAT pep4::HIS3 prb1-1.6R his3-200 lys2-801
trp1-101 (gal3) ura3-52 gal2 can1] and DKY6281 (MAT
pho8::TRP1 leu2-3 leu2-112 ura3-52 his3-200 trp1-901 lys2-801 suc2-
9). The CBP coding sequence was inserted within the Vam3p ORF
by modifying an existing vector (pFA6a-kanMX6-PGAL1-GST)
(34). A DNA fragment containing the VAM3 promoter (300 bases
upstream of initiator ATG) and coding sequences for the first 154
amino acids was amplified from yeast genomic DNA by PCR using
two oligonucleotides, one with a flanking BglII site (GAAGATCT-
CATATAGTTTACCTAGGTGCT) and the other with a flanking
PacI site (CGCGTTAATTAAGTTTACTTTTATAGAA-
ATATA). The GAL1 promoter was excised from pFA6a-kanMX6-
PGAL1-GST by BglII/PacI digestion and replaced with the
digested VAM3 promoter and partial coding region. A DNA
fragment containing the CBP coding sequence was amplified from
pBS1479 (23) by PCR using two oligonucleotides, one containing
a flanking PacI site (TCCCCCTTAATTAACAAGAGAAGAT-
GGAAAAAGAATTTC) and the other with a flanking AscI site
(TGGCGCGCCAAGTGCCCCGGAGGATGAGAT). The GST
coding sequence was excised by PacI and AscI digestion and
replaced with the digested CBP coding sequence. This vector
(pFA6a-kanMX6-PVAM3–2) was used as template for PCR with
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Fig. 5. Promotion of trans-SNARE complex assembly. (A) Added Vam7p and
HOPS. Fusion reactions contained added Vam7p. Purified HOPS complex (5
g/ml) was added after Vam7p addition (lanes 7 and 8), and MED (lane 8) was
added to one HOPS  Vam7p reaction. Vacuole fusion and CBP-Vam3p
associations were assayed after incubation (45 min, 27°C). Data are represen-
tative of three independent experiments. Bars represent the average fusion
data from the three trials, and error bars represent their standard deviation.
(B) Elevated Nyv1p on acceptor vacuoles. Fusion reactions were initiated with
vacuoles from BJ3505 CBP-Vam3p nyv1 and a DKY6281 strain which either
overproduced Nyv1p from the ADH1 promoter element ([Nyv1p]o/p, lanes 1–6;
Y. Jun and WTW, unpublished data) or bore wild type levels of Nyv1p
([Nyv1p]wt, lanes 7–12). After incubation (45 min, 27°C), reactions were placed
on ice, and fusion (black bars) and associations of CBP-Vam3p with Nyv1p (gray
bars) and other SNAREs were assayed. Vacuole detergent extracts from reac-
tions containing a single type of vacuole (CBP-Vam3p nyv1, Nyv1po/p, or
Nyv1pwt) were also prepared as in Fig. 2B. These reaction extracts were mixed
to determine the extent of Nyv1p associations that occurred in the extract
(lanes 6 and 12). Three independent experiments were averaged, and error
bars represent the standard deviation of the fusion values and the Nyv1p
associations as determined by densitometry.








CCC). This PCR product was transformed into BJ3505 and
DKY6281 yeast strains, and all G418-resistant transformants had
recombined via appended VAM3 homology engineered down-
stream of the CBP sequence. NYV1 was disrupted with the
natMX4 cassette (35) using PCR products amplified with homology





strain overexpressing Nyv1p from the ADH1 promoter (Fig. 5B)
was constructed as described previously (27).
Vacuole Fusion and Reagents. Yeast vacuoles were prepared by
flotation through discontinuous Ficoll gradients (22). Standard
fusion reactions were performed at 27°C in PIPES/sorbitol
buffer (20 mM Pipes/KOH, pH 6.8, 200 mM sorbitol) containing
125 mM KCl, 5 mM MgCl2, 10 M CoA, 38.6 g/ml Pbi2p (IB2),
an ATP regeneration system (1 mM ATP, 1 mM MgCl2, 0.5
mg/ml creatine kinase, 3 mM creatine phosphate) and 3 g of
each vacuole type. One unit of vacuole fusion activity yields 1
mol of p-nitrophenol per minute per milligram of BJ3505
vacuole protein. Vacuole fusion inhibitors and activators have
been described previously (6, 15, 19, 27, 36) and were used at the
following concentrations: His6-Sec17p (24 g/ml), anti-Sec17p
IgG (225 g/ml), anti-Vam3p Fab fragments (3 g/ml), Gdi1p
(60 g/ml), Gyp1–46p (230 g/ml), anti-Ypt7p peptide antibody
(3 g/ml), Ypt7p peptide (66 g/ml), anti-Sec18p (7 g/ml),
anti-Vps33p peptide antibody (23 g/ml), MTM-1 (115 g/ml),
SigD (115 g/ml), GST-FAPP PH domain (600 g/ml), MED
(10 M), and GST-ENTH (570 g/ml). Vam7p was purified as
a chitin-binding domain fusion protein, eluted by intein cleavage,
and added at 40 nM unless indicated. HOPS complex was
purified from a yeast strain coexpressing each subunit from a
GAL1 promoter; details of this strain’s construction and use in
HOPS purification will be published elsewhere. Bovine brain
calmodulin (Calbiochem, San Diego, CA) was labeled with
EZ-Link Sulfo NHS-LC-LC biotin (Pierce, Rockford, IL).
Assay of trans-SNARE Complexes. Standard trans-SNARE and
fusion assays were 11 the scale of fusion assays alone (above)
and contained 33-g vacuoles from BJ3505-CBP-Vam3p nyv1
and 33-g vacuoles from DKY6281. After incubation, reactions
were placed on ice (5 min), 30 l was withdrawn to assay Pho8p
maturation, and the remainder (300 l) was centrifuged
(11,000  g, 5 min, 4°C). The pellet was overlaid with ice-cold
solubilization buffer [200 l; 20 mM TrisHCl (pH 7.5), 150 mM
NaCl, 1 mM MgCl2, 1 mM imidazole, 0.5% Triton X-100, 20%
glycerol, 5 mM -mercaptoethanol, 1 protease inhibitor mix-
ture (0.46 g/ml leupeptin, 3.5 g/ml pepstatin, 2.4 g/ml
pefabloc-SC, 1 mM PMSF)], resuspended, and solubilization
buffer was added to a final volume of 400 l. The extracts were
mixed on a nutator rocker and then centrifuged (16,000  g, 20
min, 4°C). Ten percent of the extract was removed for a total
sample and the remaining extract was brought to 2 mM CaCl2.
The CBP-Vam3p was recovered with biotinylated bovine brain
calmodulin (0.3–3 g) and NeutraAvidin agarose (Pierce, 20–50
l per 400 l) with rocking overnight. In some experiments, the
biotinylated calmodulin was bound to NeutrAvidin agarose
before its addition to extracts (200 g of protein per milliliter of
beads). Beads were collected by centrifugation (3,000  g, 2 min,
4°C) and suspended four times with solubilization buffer con-
taining 0.1% Triton X-100 and 2 mM CaCl2 (600 l each)
followed by bead sedimentation. Bound proteins were eluted
with solubilization buffer containing 0.1% Triton X-100 and 5
mM EGTA. The eluates were precipitated with trichloroacetic
acid, acetone washed, and heated in sample buffer (94°C, 5 min)
for SDS/PAGE and immunoblotting. ECL exposed films were
quantitated using a BioRad Molecular Imager GS-800 Densi-
tometer using Quantity One software. All data are representa-
tive of experiments performed at least three times.
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